- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01424813
A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma
A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax® Versus Placebo in Subjects 12 Years and Older With Persistent Asthma
Přehled studie
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
Alabama
-
Birmingham, Alabama, Spojené státy
- Teva Investigational Site 10077
-
-
Arizona
-
Phoenix, Arizona, Spojené státy
- Teva Investigational Site 10079
-
-
California
-
Costa Mesa, California, Spojené státy
- Teva Investigational Site 10569
-
Fountain Valley, California, Spojené státy
- Teva Investigational Site 10053
-
Huntington Beach, California, Spojené státy
- Teva Investigational Site 10065
-
Huntington Beach, California, Spojené státy
- Teva Investigational Site 10572
-
Los Angeles, California, Spojené státy
- Teva Investigational Site 10075
-
Roseville, California, Spojené státy
- Teva Investigational Site 10061
-
San Diego, California, Spojené státy
- Teva Investigational Site 10066
-
-
Colorado
-
Denver, Colorado, Spojené státy
- Teva Investigational Site 10068
-
Denver, Colorado, Spojené státy
- Teva Investigational Site 10069
-
-
Florida
-
Miami, Florida, Spojené státy
- Teva Investigational Site 10058
-
Miami, Florida, Spojené státy
- Teva Investigational Site 10060
-
Ormond Beach, Florida, Spojené státy
- Teva Investigational Site 10064
-
-
Georgia
-
Savannah, Georgia, Spojené státy
- Teva Investigational Site 10071
-
-
Kansas
-
Wichita, Kansas, Spojené státy
- Teva Investigational Site 10073
-
-
Kentucky
-
Owensboro, Kentucky, Spojené státy
- Teva Investigational Site 10070
-
-
Maryland
-
Bethesda, Maryland, Spojené státy
- Teva Investigational Site 10063
-
Gaithersburg, Maryland, Spojené státy
- Teva Investigational Site 10571
-
Wheaton, Maryland, Spojené státy
- Teva Investigational Site 10067
-
-
Missouri
-
St. Louis, Missouri, Spojené státy
- Teva Investigational Site 10072
-
-
Montana
-
Missoula, Montana, Spojené státy
- Teva Investigational Site 10050
-
-
North Carolina
-
Raleigh, North Carolina, Spojené státy
- Teva Investigational Site 10057
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy
- Teva Investigational Site 10051
-
Sylvania, Ohio, Spojené státy
- Teva Investigational Site 10078
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy
- Teva Investigational Site 10054
-
Oklahoma City, Oklahoma, Spojené státy
- Teva Investigational Site 10568
-
Tulsa, Oklahoma, Spojené státy
- Teva Investigational Site 10055
-
-
Oregon
-
Medford, Oregon, Spojené státy
- Teva Investigational Site 10056
-
Medford, Oregon, Spojené státy
- Teva Investigational Site 10076
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy
- Teva Investigational Site 10684
-
Spartanburg, South Carolina, Spojené státy
- Teva Investigational Site 10570
-
-
Texas
-
Live Oak, Texas, Spojené státy
- Teva Investigational Site 10049
-
San Antonio, Texas, Spojené státy
- Teva Investigational Site 10052
-
Waco, Texas, Spojené státy
- Teva Investigational Site 10685
-
-
Virginia
-
Fairfax, Virginia, Spojené státy
- Teva Investigational Site 10059
-
-
Washington
-
Puyallup, Washington, Spojené státy
- Teva Investigational Site 10074
-
Tacoma, Washington, Spojené státy
- Teva Investigational Site 10062
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Written informed consent/assent
- General good health
- Persistent asthma, with an FEV1 50-80% predicted.
- Ability to perform spirometry in an acceptable manner as per protocol guidelines.
- Ability to perform PEFR with a handheld peak flow meter.
- Demonstration of reversible bronchoconstriction as verified by a 15% or greater increase from baseline FEV1.
- Taking inhaled corticosteroids at a stable dose for at least 4 weeks prior to the Screening Visit.
- Non-smokers.
- Capable of understanding the requirements, risks, and benefits of study participation.
- Other inclusion criteria apply.
Exclusion Criteria:
- Participation in any investigational drug trial within the 30 days preceding the Screening Visit (SV).
- A known hypersensitivity to albuterol or any of the excipients in the formulations.
- History of severe milk protein allergy.
- History of a respiratory infection or disorder that has not resolved within the 2 weeks preceding the Screening Visit (SV).
- Currently requires treatment with β2-adrenergic receptor antagonists or non-selective β-receptor blocking agents.
- History of life-threatening asthma that is defined for this protocol as an asthma episode that required intubation.
- Any asthma exacerbation requiring oral corticosteroids within 3 months of the Screening Visit (SV). A subject must not have had any hospitalization for asthma within 6 months prior to the Screening Visit (SV).
- Historical or current evidence of any clinically significant non-asthmatic acute or chronic condition including.
- Other exclusion criteria apply.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Komparátor placeba: Placebo MDPI
Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.
|
Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
Ostatní jména:
|
Experimentální: Albuterol MDPI
Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.
|
Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) Over the 12-week Treatment Period
Časové okno: Day 1, Day 8 and Day 85
|
FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average (by the trapezoidal rule) of FEV1 AUC 0-6 measures adjusted for the baseline measure (i.e., change from baseline at each timepoint) recorded on days 1, 8 and 85 of the treatment period. The baseline for each study day was the average of the 2 pre-dose FEV1 measurements on that study day. FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min. |
Day 1, Day 8 and Day 85
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 1
Časové okno: Day 1
|
FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day. The baseline-adjustment refers to change from baseline at each post dose timepoint recorded on Day 1. FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min. |
Day 1
|
Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 8
Časové okno: Day 8
|
FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day. The baseline-adjustment refers to change from baseline at each post dose timepoint recorded on Day 8. FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min. |
Day 8
|
Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 85
Časové okno: Day 85
|
FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day. The baseline-adjustment refers to change from baseline at each post dose timepoint recorded on Day 85. FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min. |
Day 85
|
Participants With Adverse Events
Časové okno: Day 1 to Day 92
|
Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs).
An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug.
Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities.
Relation of AE to treatment was determined by the investigator.
Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
|
Day 1 to Day 92
|
Physical Examination Findings Shifts From Baseline to Endpoint by Treatment Group
Časové okno: Day 1 (Baseline), Day 85
|
Physical exam was recorded as normal or abnormal based on physician assessment.
Format for results is: Test Baseline/Endpoint HEENT = head, eyes, ears, nose, throat
|
Day 1 (Baseline), Day 85
|
Participants With Clinically Significant Vital Sign Assessments
Časové okno: Day 8, Day 85
|
For both standard and serial vital signs, participants were seated for at least 5 minutes before vital signs were assessed. Heart rate was obtained prior to the blood pressure measurement. Serial heart rate and blood pressure were conducted in the sitting position prior to the spirometry assessment; baseline measures were taken pre-dose at -30 ± 5 and -5 minutes on Day 1. Day 85 serial vital sign measures were taken in the sitting position prior to spirometry assessments pre-dose at -30 ± 5 and -5 minutes, then post-dose at 30 (±5) minutes, 1hr (± 10 min), 2hr (± 10 min), 3hr (± 10 min), 4hr (± 10 min), 5hr (± 10 min) and 6 hr (± 10 min). Serial heart rate and blood pressure measurements that were elevated to the following criteria were considered clinically significant: Systolic blood pressure: > 160 beats/minute Diastolic blood pressure: >100 beats/minute Heart rate: >120 beats/minute |
Day 8, Day 85
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Percent Change From Baseline in FEV1 AUC 0-6 Over the 12-week Treatment Period
Časové okno: Day 1, Day 8, Day 85
|
Day 1, Day 8, Day 85
|
|
Percent Change From Baseline in FEV1 AUC 0-6
Časové okno: Day 1
|
Day 1
|
|
Percent Change From Baseline in FEV1 AUC
Časové okno: Day 8
|
Day 8
|
|
Percent Change From Baseline in FEV1 AUC
Časové okno: Day 85
|
Day 85
|
|
Maximum Percent Change From Baseline in FEV1 Within 2 Hours Post Dose Over the 12-week Treatment Period
Časové okno: Day 1, Day 8, Day 85
|
Day 1, Day 8, Day 85
|
|
Maximum Percent Change From Baseline in FEV1 Within 2 Hours Post Dose on Day 1
Časové okno: Day 1
|
Day 1
|
|
Maximum Percent Change From Baseline in FEV1 Within 2 Hours Post Dose on Day 8
Časové okno: Day 8
|
Day 8
|
|
Maximum Percent Change From Baseline in FEV1 Within 2 Hours Post Dose on Day 85
Časové okno: Day 85
|
Day 85
|
|
Time to Onset of Effect (Change in FEV1 of 12% From Baseline Within 30 Minutes Postdose)
Časové okno: Day 1, Day 8, Day 85
|
Day 1, Day 8, Day 85
|
|
Duration of Response Measured From the Time Post-dosing to the First Time After the Response Onset (Increase ≥12% Above Baseline) When the FEV1 Decreases to Less Than 12% Above Baseline (Within 6 Hours After Dosing) for Those Who Responded in 30 Minutes
Časové okno: Day 1, Day 8, Day 85
|
Day 1, Day 8, Day 85
|
|
Time to Onset of Effect (Change in FEV1 of 15% From Baseline Within 30 Minutes Postdose)for Those Who Responded in 30 Minutes
Časové okno: Day 1, Day 8, Day 85
|
Day 1, Day 8, Day 85
|
|
Duration of Response on Days 1, 8 and 85
Časové okno: Day 1, Day 8, Day 85
|
Duration of response measured from the time post-dosing to the first time after the response onset (increase ≥15% above baseline) when the FEV1 decreases to less than 15% above baseline (within 6 hours after dosing) for those who responded within 30 minutes
|
Day 1, Day 8, Day 85
|
Percent of Symptom Free Days on the Patient Diary
Časové okno: Treatment days 1 through 85
|
Treatment days 1 through 85
|
|
Percent of Rescue Medication Free Days in the Patient Diary
Časové okno: Treatment days 1 through 85
|
Treatment days 1 through 85
|
|
Morning Peak Expiratory Flow Reading Reported on Patient Diary
Časové okno: Treatment days 1 through 85
|
Treatment days 1 through 85
|
Spolupracovníci a vyšetřovatelé
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Nemoci dýchacích cest
- Onemocnění imunitního systému
- Plicní onemocnění
- Přecitlivělost, okamžitá
- Bronchiální onemocnění
- Plicní onemocnění, obstrukční
- Respirační přecitlivělost
- Přecitlivělost
- Astma
- Fyziologické účinky léků
- Adrenergní látky
- Neurotransmiterové látky
- Molekulární mechanismy farmakologického působení
- Autonomní agenti
- Agenti periferního nervového systému
- Adrenergní agonisté
- Bronchodilatační činidla
- Antiastmatická činidla
- Agenti dýchacího systému
- Činidla pro kontrolu reprodukce
- Agonisté adrenergních beta-2 receptorů
- Adrenergní beta-agonisté
- Tokolytická činidla
- Albuterol
Další identifikační čísla studie
- ABS-AS-301
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Placebo MDPI
-
Association pour le Développement et l'Organisation...Zatím nenabírámeDušnost | Vrozený syndrom centrální hypoventilace | CCHSFrancie
-
Air Force Military Medical University, ChinaThe Second Affiliated Hospital of Chongqing Medical University; Huaihe Hospital... a další spolupracovníciDokončenoEndoskopická retrográdní cholangiopankreatografie | Pankreatikobiliární onemocněníČína
-
Institut für Pneumologie Hagen Ambrock eVAktivní, ne nábor
-
University of East AngliaDokončenoDemenceSpojené království
-
Assistance Publique - Hôpitaux de ParisNáborDušnost a respirační insuficience u dětíFrancie
-
Kafrelsheikh UniversityDokončenoEndodonticky ošetřené zuby | Přední zubyEgypt
-
Medhat OsmanBlue Earth DiagnosticsDokončeno
-
American College of Radiology - Image MetrixWorld Molecular Imaging SocietyNeznámýKostní metastázySpojené státy, Austrálie, Rakousko, Portugalsko, Švýcarsko
-
Assiut UniversityZatím nenabírámeKostní metastázy | Urogenitální rakovina
-
Xinhua Hospital, Shanghai Jiao Tong University...DokončenoOsteoporóza | Diferencovaná rakovina štítné žlázyČína